Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC).

Trial Profile

Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC).

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Feb 2014

At a glance

  • Drugs Carboplatin; Glutathione/cisplatin; Glutathione/cisplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Cellectar Biosciences
  • Most Recent Events

    • 11 Feb 2014 Novelos Therapeutics now known as Cellectar Biosciences
    • 05 Jun 2010 Results presented as a late-breaking abstract at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO 2010).
    • 06 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top